Design Therapeutics (DSGN) to Release Quarterly Earnings on Wednesday

Design Therapeutics (NASDAQ:DSGN - Get Free Report) is expected to post its Q1 2025 quarterly earnings results before the market opens on Wednesday, May 14th. Analysts expect the company to announce earnings of ($0.28) per share for the quarter.

Design Therapeutics (NASDAQ:DSGN - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.03). On average, analysts expect Design Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Design Therapeutics Trading Up 2.9%

Shares of DSGN stock traded up $0.10 during trading hours on Monday, reaching $3.60. The company's stock had a trading volume of 20,469 shares, compared to its average volume of 188,170. The stock has a market capitalization of $204.37 million, a P/E ratio of -4.25 and a beta of 1.77. The firm's fifty day simple moving average is $4.04 and its 200 day simple moving average is $4.95. Design Therapeutics has a one year low of $2.60 and a one year high of $7.77.

Design Therapeutics Company Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.